Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m., Room 405

The prevalence of cancer, diabetes and cardiovascular diseases continue to rise in China, primarily due to a growing aging population and urbanization. To what extent are current standards of care falling short, and what novel products and technologies are around the corner to fill the void? Hear leading experts discuss these questions, and learn how the industry is addressing unmet medical needs to improve healthcare in China.

Moderator

• Nick Zhang, PhD, China General Manager, Senior Vice President, Frontage Lab

Panelists

• Friedhelm Blobel, PhD, President & CEO, SciClone Pharmaceuticals 
• Bruno Osterwalder, MD, Senior VP, Senior Strategic Advisor Oncology, Global Drug Development and Medical, Merck Serono
• Grace Xu, VP, Product Development & Strategic Planning, Bristol-Myers Squibb

BIO is pleased to welcome our distinguished keynotes to this year’s BIO Convention in China.

Tuesday, November 12, 2013
9:15 a.m. - 10:25 a.m.
Auditorium 

Governor Jay Inslee Washington State

Jay first became involved in public service in 1985 when he and Trudi helped lead the effort to build a new public high school in Selah. Motivated to fight against proposed funding cuts for rural schools, Jay went on to represent the 14th Legislative District in the state House of Representatives. He continued serving communities in the Yakima Valley when he was elected to Congress in 1992. The Inslees later moved back to the Puget Sound area where Jay was elected to Congress in 1998, serving until 2012. During his time in Congress, Jay became known as a forward-thinking leader, especially on issues of clean energy and the environment. As governor, Jay's top priority is growing Washington's innovative industries such as clean energy, IT and life sciences, and strengthening existing industries such as aerospace, agriculture, maritime and military. 

Gary F. Locke Ambassador of the United States of America to the People’s Republic of China

On March 9, 2011, President Barack Obama nominated Gary Locke to be the 10th Ambassador of the United States of America to the People’s Republic of China. He was confirmed by the Senate on July 27, 2011 and was sworn in on August 1, 2011. He assumed duty as the Ambassador Extraordinary and Plenipotentiary to the People's Republic of China on August 13, 2011.

Previously, Ambassador Locke served as the Secretary of Commerce where he helped implement President Obama's ambitious agenda to turn around the economy and put people back to work. As the administration’s point person for achieving the President’s National Export Initiative, he presided over a 17 percent increase in exports from 2009 to 2010, while exports to China saw a 32 percent increase. Ambassador Locke also oversaw a significant first step in the president’s export control reform effort that strengthens national security, while making U.S. companies more competitive by easing their licensing burden for exports to partners and allies.

Bian Zhenjia Assistant Minister China Food and Drug Administration (CFDA)

Mr. Bian Zhenjia currently is the Assistant Minister of the China Food and Drug Administration (CFDA) and is one of the nine Party Group members of CFDA. Bian started serving this position since March 2013. Prior to this, Bian was the Deputy Commissioner of the State Food and Drug Administration (SFDA), a position he has served in since March 2009.

He had been working at SFDA more than 20 years including various positions as DG and DDG of Drug Safety Administration, DDG of Science and Education. Prior to the post in SFDA, he had been working at Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences for many years. He served as Deputy President, Director of Science development division, deputy director of science and research, deputy director of general office etc.

Mr. Bian graduated from Beijing Medical College majored in Medicine in 1977. From August 1996 to February 1997, Bian studied public health management in the University of North Carolina in the U.S. Mr. Bian born in 1953, Lishu City of Jilin Province.

Zhao Yajun Director General China Center for Pharmaceutical International Exchange

Mr. Zhao Yajun has been the DG of CCPIE since 2002. Prior to that, he was the Division Director of the International Cooperation Department of State Food and Drug Administration.

Mr. Zhao Yajun has worked in international cooperation and has a significant experience in international regulatory exchange.

James C. Greenwood President and CEO Biotechnology Industry Organization

James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Since his appointment in January of 2005, he has markedly enhanced the trade association’s capacity – increasing both its staff and budget by nearly fifty percent. BIO is now a world class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally.

Mr. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992). Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield, Pennsylvania.

Wednesday, November 13, 2013, 1:00 p.m. - 1:55 p.m., Room 403

Through in-licensing, out-licensing, JV/Alliances and M&A, an increasing number of Chinese and Western companies are collaborating to bring therapeutics to the market. Panelists will discuss what companies need to consider in order to produce the most fruitful partnerships and where they see China and Western collaborations moving in the future.

Moderator:

• Weishi Li, Partner, Covington & Burling LLP

Panelists:

• Jie Liu D’Elia, PhD, Executive Director, Business Development, Bristol-Myers Squibb
• Mike Liu, PhD, Head of Global Business Development, HengRui Pharmaceuticals
• Xiaoming Zou, PhD, Chief Business Officer, Eddingpharm
• Tony Zhang, PhD, Senior Director, Business Development, MSD China

Tuesday, November 12, 2013, 3:00 p.m. - 3:55 p.m., Room 405

With capital markets opening up, 2013 saw 38 (and counting) new biotech IPOs – many of which are staying strong even after their initial debut. Will this excitement continue onto 2014 and translate into new opportunities for China? This panel will explore the state of the capital markets in China in comparison to the exciting new developments in the U.S. through the prism of biotech insiders, as well as assess the current and future attractiveness of local IPOs, providing a global and insightful perspective to both companies and investors.

Moderator:

• John V. Oyler, Founder and CEO, BeiGene

Panelists:

• Howard Liang, PhD, Managing Director, Biotechnology Equity Research, Leerink Swann
• David Thomas, CFA, Director, Industry Research & Analysis, BIO
• Asish K. Xavier, PhD, Vice President, Venture Investments, J&J Development Corporation

Wednesday, November 13, 2013, 1:00 p.m. - 1:55 p.m, Room 405

While there are still only a few early-stage bio-investors in China, the number of funding sources is starting to increase. Who is funding this innovation and what are their ultimate goals? Among them are international investment funds that have established China-based funds; corporations investing through their own venture arms, or as limited partners in funds; domestic VC firms; and government implemented programs, such as the successful Torch program from the Ministry of Science and Technology. All these funding resources are kick-starting Chinese biotech today. Where will this diversity of investments take China’s biotech industry in the coming years? Hear investors assess the current state of early-stage VC funding in China and the long-term outlook for biotech.

Moderator:

• Lianyong (Leon) Chen, Founder & Managing Partner, Frontline BioVentures

Panelists:

• Jonathan Wang, PhD, Senior Managing Director, OrbiMed Healthcare Fund Management

• Jimmy Zhang, PhD, Managing Director, MSD Early Investments, Greater China, Merck & Co.

• Yi Shi, PhD, Managing Director, Lilly Asia Ventures

Wednesday, November 13, 2013, 11:00 a.m. - 11:55 a.m., Room 403

China has committed to making private healthcare a larger part of the overall ecosystem, aiming for 20% of beds and 20% of spending to be conducted through private institutions by 2020. In order achieve this ambitious goal, the government has laid out multiple policy initiatives aiming to relax historical constraints that have previously limited growth. These changes have unleashed a wave of growth in private healthcare that is only just beginning. In this panel, we will explore the opportunities and challenges for private insurers, providers, pharmaceutical companies and device manufacturers looking to capitalize on the rapidly growth in private healthcare.

Moderator:

• Maykin Ho, PhD, Advisory Director, Goldman Sachs

Panelists:

• Helen Chen, Director & Partner, L.E.K Consulting
• Peter Liu, MD, Director and Founder, Delta Health
• Lawrence Wang, MD, Managing Director, Primavera Capital Group

Who's Who

	Helen Chen Director & Partner, L.E.K. Consulting Helen Chen is a Director and Partner at L.E.K. Consulting and is the Co-Head of the China practice in Shanghai. She is also the head of L.E.K.’s China Biopharmaceuticals & Life Sciences practice and has extensive case work and industry experience covering the full biopharmaceutical value chain, ranging from early research services and portfolio evaluations to post-market product positioning and sales force effectiveness. Helen has more than 23 years of consulting and industry experience in the U.S. and Asia markets and has resided in China since 2000. She helps companies expand their presence in China and leverages China’s resources to improve their global businesses. She is on the Editorial Board of PharmAsia and is a frequent speaker and author on the opportunities and issues in China’s Healthcare and Life Sciences sectors. Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. Helen has an honors degree in Applied Mathematics from Harvard University and attended the Kellogg Graduate School of Management at Northwestern University.
	Maykin Ho, PhD Advisory Director, Goldman Sachs Dr. Ho is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. She joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002. Dr. Ho has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company. Dr. Ho serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School. Dr. Ho was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center.
	Peter Liu, MD, Director and Founder Director and Founder, Delta Health *Biography coming soon.
	Lawrence Wang, MD Managing Director, Primavera Capital Group Lawrence is currently managing director and head of healthcare for Primavera Capital. Previous to joining Primavera, he was Head of Asia Healthcare for Macquarie Capital and prior to Macquarie, was an Executive Director in Goldman Sachs with roles in GS Direct Asia in Hong Kong and healthcare investment banking both in Hong Kong and New York. Lawrence holds a Bachelor of Arts in Biology and Economics and a Doctor of Medicine from Boston University and an MBA from MIT Sloan School of Management.

Wednesday, November 13, 2013, 3:30 p.m. - 4:25 p.m, Room 403

This panel will look at current opportunities for global biotech transfer in China, what development funds are available, and how they promote the development of the industry.

Panelists:

• Samantha Du, Managing Director, Sequoia Capital China

• Syd Hanna, Partner, Elixir Ventures

• Simon Harworth, CEO, Dynasty Biotechnology Limited

• Dave Tapolczay, CEO, Medical Research Council Technology

Wednesday, November 13, 2013, 9:00 a.m. - 10:55 a.m
Organized by NewSummit Biopharma

This panel will explore the current state of international multi-center clinical trials in China as well as policy support for drugs originally developed in China. Specifically, this conversation will reference translational and evidence-based medicine supported by the “national project” and its use of third-party evaluations. Panelists will delve into the issue of post-market evaluations and their role in improving the standardization of clinical medicine. Determining international standards in China for multi-center clinical trials and how to accelerate the process of overseas R&D efforts will serve as core themes throughout the discussion.

Panelists:

• Wen Aidong, Director, Drug Clinical Trial Department, the Fourth Military Medical University

First Affiliated Hospital

• Chen Biao, Director, Beijing Xuanwu Hospital

• Li Qing, Director, Development Center for Medical Science and Technology, Ministry of Health

• Wang Xin, Chairman, Beijing Bionovo

• Huang Yangbin, Chief Technology Officer, Shanghai Newsummit Biopharma Group

Panelists:

• Hongguang Wang, Director General of China National Centre for Biotechnology Development (CNCBD)

Tuesday, November 12, 2013, 1:00 p.m. - 4:25 p.m., Room 402 A & B

The bio-industry has been designated as one of China’s seven strategic emerging industries (SEI) by the government. Within the bio-industry, therapeutic biologics hold significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in many disease areas. Today, China’s therapeutic biologics industry stands at RMB 18 billion, representing less than 2 percent of the global total. This panel will explore the steps that may be taken by the government and industry to develop a world-class innovative biologics sector in China.

Policy Focused Speeches:

• International Policy Environment and Trends in the Global Biotechnology Industry
• China Bio-industry Policies & Competencies
• Building a World-Class Innovative Therapeutic Biologics Industry in China

Panelists:

• James Cai, Early Clinical Development Strategy Lead for APAC, Genentech
• Joseph Cho, Managing Director, R&D-based Pharmaceutical Association Committee (RDPAC)
• Joseph Damond, Senior Vice President of International Affairs, BIO
• Hongguang Wang, Advisor, Deputy Director, Chinese Academy of Science and Technology for Development (CASTED), Ministry of Science and Technology (MoST)
• Michael Yu, CEO, Innovent Biologics